Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444135 | 0.94 | NOS1 (0.37) | ARNOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL2731412 | 0.88 | — | — | |
| SCHEMBL13484265 | 0.88 | — | — | |
| SCHEMBL13484370 | 0.88 | — | — | |
| SCHEMBL3499721 | 0.87 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1ALOX5TP53 | |
| SCHEMBL14285557 | 0.83 | — | — | |
| SCHEMBL94282 | 0.83 | — | — | |
| SCHEMBL1423906 | 0.83 | ALDH1A1 (0.41) | NOS1NOS2ALDH1A1L3MBTL1ALOX5 | |
| SCHEMBL9800093 | 0.82 | ALDH1A1 (0.46) | NOS1NOS2ALDH1A1L3MBTL1ALOX5 | |
| SCHEMBL7717336 | 0.82 | CYP1A2 (0.42) | NOS1NOS2ALDH1A1L3MBTL1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112334527-A | Foam particles based on long-chain polyamides | 巴斯夫欧洲公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-106029776-B | Molding materials based on vinyl aromatic/diene block copolymers for 3-D printing | 英力士苯领集团股份公司 | 2019-12-31 | — | — | CN | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
| CN-1317790-C | Nonaqueous electrolyte and secondary lithium battery using the same | MITSUBISHI CHEM CORP (JP) | 2007-05-23 | — | — | CN | disclosed |
| US-20060172201-A1 | Non-aqueous electrolyte and lithium secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| US-6774126-B2 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| EP-1357628-A1 | NONAQUEOUS ELECTROLYTIC LIQUIDS AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6552052-B2 | (2S,3Z)-2-amino-5-(6,7,8,9-tetrahydro-3-oxo-3H,5H -(1,2,4)oxadiazolo(4,3-a)azepin-5-yl)-3-pentenoic acid, for example | MONSANTO/G.D. SEARLE | 2003-04-22 | — | — | US | disclosed |
| CN-1411619-A | Nonaqueous electrolyte and secondary lithium battery using the same | MITSUBISHI CHEM CORP (JP) | 2003-04-16 | — | — | CN | disclosed |
| US-6489323-B1 | INHIBITING NO PRODUCTION FROM L-ARGININE, AS SEEN IN DISEASE STATES SUCH AS ARTHRITIS AND SYSTEMIC HYPOTENSION ASSOCIATED WITH SEPTIC AND/OR TOXIC SHOCK | G.D. SEARLE & CO. | 2002-12-03 | — | — | US | disclosed |
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | HANSEN DONALD W (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1086108-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. Searle & Co. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064426-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-4083689-A | Solid ε-caprolactam dyestuff preparations | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | AR 3907/4885NOS3 3/4885NOS1 1/4885 |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | AR 3264/4885NOS3 1392/4885NOS1 2157/4885 |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | AR 4605/4885NOS3 3/4885NOS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.